Metaplastic breast cancer is a rare and aggressive form of breast cancer that accounts for less than 1% of all invasive breast cancers, yet it behaves worse than most other subtypes and responds poorly to standard chemotherapy.1PubMed Central. A comprehensive overview of metaplastic breast cancer: Features and treatments What sets it apart is cellular shape-shifting: the cancer cells differentiate into tissue types not normally found in the breast, including squamous cells, spindle cells, and even bone- or cartilage-like tissue. That biological quirk makes it harder to diagnose, harder to treat, and the subject of growing interest in newer therapies like immunotherapy and antibody-drug conjugates.
How Metaplastic Breast Cancer Typically Presents
The most common first sign is a palpable lump, and it tends to be a large one. Compared with the more common forms of invasive breast cancer, metaplastic tumors are often bigger at the time of diagnosis and higher in histologic grade, meaning the cells look more abnormal under a microscope.2ONCOLOGY. A 40-Year-Old Woman With a New Triple-Negative Breast Mass, Shown on Biopsy to Be Metaplastic Carcinoma There is nothing unique about the lump itself from the patient’s perspective: it feels firm, may grow quickly, and can cause skin changes or discomfort as it enlarges. The symptoms overlap almost entirely with those of other breast cancers, so you cannot distinguish metaplastic from non-metaplastic on touch or appearance alone.
One counterintuitive feature is that axillary lymph nodes are frequently uninvolved at the time of diagnosis, despite the tumor’s aggressive biology.3PubMed Central. Metaplastic breast cancer with a unique presentation and complete response to chemotherapy: a case report In most breast cancers, a high-grade, fast-growing tumor that has reached a large size is also likely to have spread to nearby lymph nodes. Metaplastic breast cancer breaks that pattern. Evidence suggests these tumors favor spreading through blood vessels rather than lymphatic channels, which helps explain why they can skip the lymph nodes and show up instead in the lungs, bones, or brain.4PubMed Central. Metaplastic Breast Cancer: Characteristics and Survival Outcomes
The vast majority of metaplastic breast cancers are triple-negative, meaning they lack estrogen receptors, progesterone receptors, and HER2 overexpression. In one study of 41 cases, about 83% were triple-negative.5PubMed Central. PD-L1 Expression in Metaplastic Breast Carcinoma Using the PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical Assays That triple-negative status takes hormone therapy and HER2-targeted drugs off the table from the start, narrowing the conventional treatment toolbox considerably.
Why Diagnosis Can Be Tricky
Metaplastic breast cancer is not just rare; it actively resists easy identification. On mammography and ultrasound, it shows up as a mass with irregular shape and indistinct margins, which describes many breast cancers and even some benign conditions.6Egyptian Journal of Radiology and Nuclear Medicine. Metaplastic breast carcinoma: an overview of the radio-pathologic features in retrospective cohort tertiary hospital There is no imaging signature that reliably says “this is metaplastic.” Worse, imaging findings can sometimes mimic benign tumors such as phyllodes tumors, potentially delaying the correct diagnosis.7PubMed Central. Aggressive Metaplastic Carcinoma of the Breast with Osteoclastic Giant Cells
Even biopsy results can mislead. Because the tumor contains a patchwork of different tissue types, a needle biopsy may sample a benign-looking area and miss the malignant component entirely. When imaging looks aggressive but the biopsy comes back negative, that discordance should raise a red flag for additional workup.8PubMed Central. When Something Seems Amiss: Radiology-Pathology Correlation of Metaplastic Breast Cancer Radiologists aware of this diagnostic pitfall are more likely to push for repeat biopsy or excision when something does not add up, which is why experience with this rare subtype matters.
The Molecular Landscape
Understanding why metaplastic breast cancer behaves differently from other triple-negative cancers starts with its DNA. These tumors carry a distinctive pattern of mutations concentrated in a handful of genes. The most commonly altered is TP53, found in roughly two-thirds of cases, followed by PIK3CA and PTEN.9PubMed. Phenotypic and molecular dissection of metaplastic breast cancer and the prognostic implications One study of 19 cases found TP53 mutations in about 68%, PIK3CA in 42%, and PTEN in about 16%.10PLoS ONE. Mutation and immune profiling of metaplastic breast cancer: Correlation with survival What makes the mutation profile especially interesting is that these three genes sometimes appear mutated simultaneously in the same tumor, a combination that activates the PI3K/AKT/mTOR growth-signaling pathway and points toward potential drug targets.
Beyond individual mutations, metaplastic breast cancers are closely linked to a biological process called epithelial-to-mesenchymal transition, or EMT. In this process, cancer cells shed their normal epithelial characteristics and adopt traits associated with connective tissue: they become more mobile, more invasive, and take on stem cell-like properties.11PubMed Central. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes This is a big part of why the tumors contain such diverse cell types and why they are so resistant to chemotherapy. The EMT signature correlates with lower rates of complete response to standard drug regimens.
Chemotherapy Resistance
One of the most frustrating aspects of managing metaplastic breast cancer is how poorly it responds to the chemotherapy regimens that work reasonably well in other triple-negative breast cancers. When chemotherapy is given before surgery (called neoadjuvant chemotherapy), the goal is to shrink the tumor enough to make surgery easier and to gauge how sensitive the cancer is to the drugs being used. In standard triple-negative breast cancer, complete pathologic response rates to neoadjuvant chemotherapy often range from roughly 30% to 50%. In metaplastic breast cancer, one study found that rate to be just 11%.12PubMed Central. Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy
That poor response is not because oncologists are using the wrong drugs; it reflects the underlying biology of the tumor. The stem cell-like characteristics driven by EMT, combined with the heterogeneous cellular makeup, appear to give these cancers built-in mechanisms to survive chemotherapy exposure. Cells that look and behave like mesenchymal tissue simply do not respond to the same poisons that kill rapidly dividing epithelial cells.
Surgical Options
Given the aggressive nature of metaplastic breast cancer, many patients and oncologists historically assumed that mastectomy was the safer surgical choice. But the evidence does not clearly support that assumption. A systematic review and meta-analysis that pooled data from multiple studies found no significant difference in overall survival between breast-conserving surgery (wide local excision) and mastectomy.13PubMed Central. Breast conservation versus mastectomy for metaplastic breast cancer: A systematic review and meta‐analysis Both approaches appear to be reasonable when combined with radiation and appropriate systemic therapy, and the decision can be individualized based on tumor size, location, and patient preference.
No formal surgical guidelines exist specifically for metaplastic breast cancer, so treatment teams generally follow the framework used for other aggressive breast cancers while factoring in the unique features of this subtype. Since these tumors tend to be larger at diagnosis, mastectomy may be the practical choice in some cases simply because the tumor is too large for breast conservation with acceptable cosmetic results.
Radiation Therapy Makes a Measurable Difference
If there is one area where evidence is fairly consistent in metaplastic breast cancer, it is the benefit of radiation therapy. A large analysis using the SEER cancer registry found that radiation improved both overall survival and breast cancer-specific survival, with the benefit holding up after statistical adjustment for other factors. After matching patients to account for differences in age, stage, and surgery type, those who received radiation had about a 36% lower risk of dying compared with those who did not.14PubMed Central. The role of radiotherapy in metaplastic breast cancer: a propensity score-matched analysis of the SEER database
Radiation benefited patients regardless of whether they had a lumpectomy or mastectomy. In a separate analysis, radiation following lumpectomy was associated with a roughly 50% reduction in the risk of death, and mastectomy patients also saw improved overall survival with post-mastectomy radiation.15PubMed Central. Metaplastic Breast Cancer: To Radiate or Not to Radiate? A smaller institutional study reinforced these patterns, showing that radiation improved local control rates to over 90% at one year for lumpectomy patients, compared with under 70% without it.16International Journal of Radiation Oncology, Biology, Physics. Metaplastic Breast Cancer: Outcomes and Treatment Patterns In a cancer that resists chemotherapy, radiation’s consistent contribution to local control and survival is especially valuable.
Targeted Therapies Aimed at the PI3K Pathway
Because metaplastic breast cancer so commonly carries mutations in PIK3CA, PTEN, and related genes, the PI3K/AKT/mTOR signaling pathway has become the most obvious therapeutic target. Early results, while limited to small cohorts and case reports, show enough promise to justify larger trials.
In one early-phase study, patients with metaplastic breast cancer treated with regimens that included mTOR or PI3K pathway inhibitors alongside chemotherapy achieved a response rate of about 25% to 35%, with a few patients achieving durable complete responses lasting years.17Annals of Oncology. PI3K/Akt/mTOR pathway inhibitors in metaplastic breast cancer One patient treated with a combination of a PI3K inhibitor (buparlisib) and paclitaxel had a partial response lasting 17 months and an overall survival of 42 months after developing metastatic disease, which is remarkable for a cancer type where metastatic outcomes are typically measured in months rather than years.18PubMed. PI3K inhibitor provides durable response in metastatic metaplastic carcinoma of the breast: A hidden gem in the BELLE-4 study In that case, the tumor regrew when the PI3K inhibitor was stopped due to side effects, and then responded again when the drug was restarted, providing strong evidence that the targeted drug was driving the clinical benefit.
These results are from small studies and individual case reports, so they are far from practice-changing on their own. But they point toward a treatment strategy that matches the biology of the disease in a way that conventional chemotherapy does not. Multiple potentially targetable features are overrepresented in metaplastic breast cancer, including not just PI3K pathway alterations but also DNA repair deficiency signatures and WNT pathway changes.19PubMed Central. Metaplastic Breast Cancer: Current Understanding and Future Directions
Immunotherapy and PD-L1
Metaplastic breast cancer has an unusually high rate of PD-L1 expression, a protein that cancer cells use to hide from the immune system. In one study using multiple PD-L1 assays, 86% to 95% of metaplastic breast cancer samples were PD-L1-positive.5PubMed Central. PD-L1 Expression in Metaplastic Breast Carcinoma Using the PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical Assays That high expression makes immunotherapy with checkpoint inhibitors a natural candidate, and there are encouraging case reports. One patient with triple-negative metaplastic breast cancer treated with pembrolizumab (an anti-PD-1 drug) plus chemotherapy achieved a complete response.20PubMed Central. Complete Response of Triple-Negative Metaplastic Carcinoma of the Breast Using Pembrolizumab
The picture is complicated, though. The large KEYNOTE-522 trial, which established pembrolizumab as part of standard treatment for triple-negative breast cancer, reported similar outcomes regardless of PD-L1 status, while the IMpassion130 trial with atezolizumab found greater benefit in PD-L1-positive patients. Whether PD-L1 testing should guide immunotherapy decisions in metaplastic breast cancer specifically remains unclear.20PubMed Central. Complete Response of Triple-Negative Metaplastic Carcinoma of the Breast Using Pembrolizumab For now, immunotherapy is being incorporated into treatment based on the broader triple-negative breast cancer guidelines, with hopes that the high PD-L1 expression in metaplastic tumors may translate into above-average benefit.
Antibody-Drug Conjugates as a Newer Option
Antibody-drug conjugates, or ADCs, represent one of the most exciting developments for hard-to-treat breast cancers. These drugs use an antibody to deliver a cytotoxic payload directly to tumor cells, sparing more of the healthy tissue. Sacituzumab govitecan, approved for metastatic triple-negative breast cancer, has shown striking responses in metaplastic breast cancer case reports even after multiple prior lines of therapy had failed.
In one reported case, a patient whose cancer had progressed through anthracycline, taxane, platinum, and pembrolizumab achieved a complete metabolic response with sacituzumab govitecan.21Annals of Case Reports. Case Report on Complete Response to Treatment of Metastatic Metaplastic Breast Cancer with Sacituzumab Govitecan In another case, a 72-year-old patient who had failed immunotherapy with atezolizumab and nab-paclitaxel sustained a clinical response for nearly a year on sacituzumab govitecan.22Current Problems in Cancer: Case Reports. A rare case of advanced metaplastic breast carcinoma with response to treatment with Sacituzumab govitecan These are single cases, and the drug has not been specifically evaluated in a metaplastic breast cancer trial, but for a cancer that shrugs off most conventional therapies, any sustained responses are worth noting.
Prognosis Compared With Other Triple-Negative Cancers
Because most metaplastic breast cancers are triple-negative, the natural comparison is with standard triple-negative breast cancer, and the comparison is unfavorable. In one institutional study, patients with metaplastic breast cancer had significantly worse disease-free survival and overall survival than matched triple-negative breast cancer patients.23PubMed Central. Metaplastic Carcinoma of the Breast Is More Aggressive Than Triple-negative Breast Cancer: A Study From a Single Institution and Review of Literature Another study put specific numbers on the gap: three-year progression-free survival was about 51% for metaplastic versus 82% for triple-negative, and three-year overall survival was roughly 68% versus 94%.24PubMed Central. Metaplastic Breast Carcinoma Versus Triple-Negative Breast Cancer: Survival and Response to Treatment
Those numbers are sobering, but they represent averages across a group of tumors that is itself highly varied. Metaplastic breast cancer encompasses several histologic subtypes with differing biology.
How Subtype Affects Outlook
Not all metaplastic breast cancers carry the same prognosis. In a study of 132 patients, those with heterologous mesenchymal metaplastic breast cancer, meaning tumors that differentiated into bone or cartilage-like tissue, had the best five-year breast cancer-specific survival at about 88%. Squamous metaplastic breast cancer had the worst, at roughly 56%.25PubMed. Survival Outcomes for Metaplastic Breast Cancer Differ by Histologic Subtype The difference between those two numbers is wide enough to matter for treatment planning and patient counseling.
Not every study agrees on this point. Another analysis found that histologic subtype did not significantly correlate with local or distant disease control.26PubMed. Predictive factors on outcomes in metaplastic breast cancer The discrepancy likely reflects small sample sizes and differences in how subtypes were categorized. With a cancer this rare, building large enough cohorts to detect true subtype-specific differences is genuinely difficult, and the evidence on this question is still evolving. What is clear is that “metaplastic breast cancer” is not a single disease. The umbrella term covers tumors that may include squamous cells, spindle cells, bone or cartilage components, or mixtures of several, and that heterogeneity almost certainly influences how a given patient’s cancer will behave.19PubMed Central. Metaplastic Breast Cancer: Current Understanding and Future Directions
Where Metaplastic Breast Cancer Tends to Spread
When metaplastic breast cancer does metastasize, it often bypasses the usual lymph node staging that oncologists rely on in other breast cancers. Instead, the spread tends to follow blood vessels to distant organs, with the lungs, bones, and brain being the most commonly affected sites.4PubMed Central. Metaplastic Breast Cancer: Characteristics and Survival Outcomes This pattern means that a patient can have a negative sentinel lymph node biopsy and still develop distant metastases later, which is unusual compared with the more stepwise progression seen in many other breast cancers. The practical implication is that surveillance strategies may need to pay particular attention to lung and bone imaging rather than relying primarily on lymph node assessment to gauge risk of recurrence.
This hematogenous (blood-borne) spread pattern also raises questions about whether the standard staging systems, which weight lymph node involvement heavily, fully capture the metastatic risk in metaplastic breast cancer. A patient with a large, high-grade tumor but no lymph node involvement might be categorized as lower stage than her actual recurrence risk warrants. Awareness of this disconnect is growing among oncologists who specialize in rare breast cancer subtypes, but formal staging modifications have not been adopted.